Left to Right- Narayanan Venkatasubramanian (CEO), Anand Budni (CTO), Shridhar Narayanan (CSO), and Amit Mahajan (Chief Data Scientist)_ Peptris.AI drug discovery startup Peptris has raised ₹70 crore in a Series A funding round led by IAN Alpha Fund and Speciale Invest.
The round also saw participation from Tenacity Ventures, BYT Ventures and other investors.
The fresh capital will be used to advance existing programs into clinical development, initiate new novel chemical entity (NCE) programs, and scale drug repurposing initiatives over the next 24 months.
“Our mission has been to harness AI to address meaningful healthcare challenges that enhance quality of life, not merely extend lifespan. Peptris is especially encouraged to have IAN Alpha Fund share this conviction as an early backer, reinforcing our commitment to building impactful, patient-centered innovation,” said Narayanan Venkatasubramanian, co-founder & CEO, Peptris.
Founded in 2019, Peptris has built an AI-led discovery engine focused on tackling inefficiencies in pre-clinical drug development, a stage often faced by high failure rates and long timelines.
The startup’s proprietary AI models are designed to predict key drug development parameters early in the process.
The company said its platform has already led to the discovery of NCEs as well as drug repurposing and rescue opportunities, with multiple programs advancing toward clinical development.
The Bengaluru-based firm currently operates on a B2B model, partnering with pharmaceutical, biotech and select FMCG firms to license assets and co-develop programs.
It majorly focuses on therapeutic areas including rare diseases, inflammation, oncology and women’s health.
The company said it will also expand its teams across biology, chemistry, data science and AI, while building business development capabilities in the US and Europe to build partnerships with global pharmaceutical and biotech firms.
Leave a Reply